Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Gene Therapy Market, By Indication
7.1. Gene Therapy Market, By Indication Type, 2020-2030
7.1.1. Acute Lymphoblastic Leukemia (ALL)
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Inherited Retinal Disease
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Large B-cell Lymphoma
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. ADA-SCID
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Melanoma (lesions)
7.1.5.1. Market Revenue and Forecast (2016-2030)
7.1.6. Beta-Thalassemia Major/SCD
7.1.6.1. Market Revenue and Forecast (2016-2030)
7.1.7. Head & Neck Squamous Cell Carcinoma
7.1.7.1. Market Revenue and Forecast (2016-2030)
7.1.8. Peripheral Arterial Disease
7.1.8.1. Market Revenue and Forecast (2016-2030)
7.1.9. Spinal Muscular Atrophy (SMA)
7.1.9.1. Market Revenue and Forecast (2016-2030)
7.1.10. Others
7.1.10.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Gene Therapy Market, By Vector Type
8.1. Gene Therapy Market, By Vector Type, 2020-2030
8.1.1. Lentivirus
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. AAV
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Retrovirus & gamma Retrovirus
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Modified Herpes Simplex Virus
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Adenovirus
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Non-viral Plasmid Vector
8.1.6.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Gene Therapy Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Indication (2016-2030)
9.1.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.1.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.1.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.6.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.6.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.6.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.5.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.5.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
Chapter 10. Company Profiles
10.1. REGENXBIO, Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Oxford BioMedica plc
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Dimension Therapeutics, Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Bristol-Myers Squibb Company
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. SANOFI
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Applied Genetic Technologies Corporation
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. F. Hoffmann-La Roche Ltd.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Bluebird Bio, Inc.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Novartis AG
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
10.11. UniQure N.V.
10.11.1. Company Overview
10.11.2. Product Offerings
10.11.3. Financial Performance
10.11.4. Recent Initiatives
10.12. Shire Plc
10.12.1. Company Overview
10.12.2. Product Offerings
10.12.3. Financial Performance
10.12.4. Recent Initiatives
10.13. Cellectis S.A.
10.13.1. Company Overview
10.13.2. Product Offerings
10.13.3. Financial Performance
10.13.4. Recent Initiatives
10.14. Sangamo Therapeutics, Inc.
10.14.1. Company Overview
10.14.2. Product Offerings
10.14.3. Financial Performance
10.14.4. Recent Initiatives
10.15. Orchard Therapeutics
10.15.1. Company Overview
10.15.2. Product Offerings
10.15.3. Financial Performance
10.15.4. Recent Initiatives
10.16. Gilead Lifesciences, Inc.
10.16.1. Company Overview
10.16.2. Product Offerings
10.16.3. Financial Performance
10.16.4. Recent Initiatives
10.17. Benitec Biopharma Ltd.
10.17.1. Company Overview
10.17.2. Product Offerings
10.17.3. Financial Performance
10.17.4. Recent Initiatives
10.18. Sibiono GeneTech Co., Ltd.
10.18.1. Company Overview
10.18.2. Product Offerings
10.18.3. Financial Performance
10.18.4. Recent Initiatives
10.19. Shanghai Sunway Biotech Co., Ltd.
10.19.1. Company Overview
10.19.2. Product Offerings
10.19.3. Financial Performance
10.19.4. Recent Initiatives
10.20. Gensight Biologics S.A.
10.20.1. Company Overview
10.20.2. Product Offerings
10.20.3. Financial Performance
10.20.4. Recent Initiatives
10.21. Transgene
10.21.1. Company Overview
10.21.2. Product Offerings
10.21.3. Financial Performance
10.21.4. Recent Initiatives
10.22. Calimmune, Inc.
10.22.1. Company Overview
10.22.2. Product Offerings
10.22.3. Financial Performance
10.22.4. Recent Initiatives
10.23. Epeius Biotechnologies Corp.
10.23.1. Company Overview
10.23.2. Product Offerings
10.23.3. Financial Performance
10.23.4. Recent Initiatives
10.24. Astellas Pharma, Inc.
10.24.1. Company Overview
10.24.2. Product Offerings
10.24.3. Financial Performance
10.24.4. Recent Initiatives
10.25. American Gene Technologies
10.25.1. Company Overview
10.25.2. Product Offerings
10.25.3. Financial Performance
10.25.4. Recent Initiatives
10.26. BioMarin Pharmaceuticals, Inc.
10.26.1. Company Overview
10.26.2. Product Offerings
10.26.3. Financial Performance
10.26.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms